Differential expression of vesicular monoamine transporter (VMAT) 1 and 2 in gastrointestinal endocrine tumours
- 28 September 2001
- journal article
- research article
- Published by Wiley in The Journal of Pathology
- Vol. 195 (4) , 463-472
- https://doi.org/10.1002/path.973
Abstract
Neuroendocrine tumours are characterized by their capacity to produce hormones, which are stored in vesicles and secretory granules. Demonstration of granule/vesicle proteins in tumours is taken as evidence of neuroendocrine differentiation. Vesicular monoamine transporters (VMAT1 and VMAT2) mediate the transport of amines into vesicles of neurons and endocrine cells. The expression of VMAT1 and VMAT2 and the usefulness of VMAT1 and VMAT2 in the histopathological diagnosis of gastrointestinal endocrine tumours have not been fully explored. This study therefore investigated the expression of VMAT1 and VMAT2 in 211 human gastrointestinal tumours by immunocytochemistry and western blotting. VMAT1 and/or VMAT2 were demonstrated in the majority of amine‐producing endocrine tumours of gastric, ileal, and appendiceal origin. Serotonin‐producing endocrine tumours (ileal and appendiceal carcinoids) expressed predominantly VMAT1, while histamine‐producing endocrine tumours (gastric carcinoids) expressed VMAT2 almost exclusively. In peptide‐producing endocrine tumours such as rectal carcinoids and endocrine pancreatic tumours, only a small number of immunopositive tumour cells were observed. No labelling was found in non‐endocrine tumours, including gastric, colorectal and pancreatic adenocarcinomas and gastrointestinal stromal tumours. In conclusion, VMAT1 and VMAT2 are differentially expressed by gastrointestinal endocrine tumours, with a pattern specific for each tumour type, reflecting their neuroendocrine differentiation and origin. VMAT1 and VMAT2 may therefore become valuable markers in the classification of neuroendocrine tumours and may also indicate patients suitable for radioisotope treatment operating via these transporter systems. Copyright © 2001 John Wiley & Sons, Ltd.Keywords
Funding Information
- the Swedish Cancer Society (3911)
- The Swedish MRC (5220)
- I. B. & A. Lundberg Research Foundation
- Assar Gabrielsson Foundation
- The Swedish Society of Medicine
- The Swedish Society for Medical Research
- The Göteborg Medical Society
- The King Gustav V Jubilee Clinic Cancer Fund, Göteborg
- Sahlgrenska University Hospital Research Funds
- Gunvor & Josef Anérs Stiftelse
- Axel Linders Stiftelse
- Gunnar, Arvid & Elisabet Nilssons Stiftelse
- Serena Ehrenströms Stiftelse
This publication has 17 references indexed in Scilit:
- Histological Typing of Endocrine TumoursPublished by Springer Nature ,2000
- Expression of Vesicular Monoamine Transporters in Endocrine Hyperplasia and Endocrine Tumors of the Oxyntic StomachDigestion, 1999
- A novel nonneuronal catecholaminergic system: exocrine pancreas synthesizes and releases dopamine.Proceedings of the National Academy of Sciences, 1996
- Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter.Proceedings of the National Academy of Sciences, 1996
- Functional Identification and Molecular Cloning of a Human Brain Vesicle Monoamine TransporterJournal of Neurochemistry, 1993
- Neurotransmitter Transporters: Recent ProgressAnnual Review of Neuroscience, 1993
- Expression cloning of a reserpine-sensitive vesicular monoamine transporter.Proceedings of the National Academy of Sciences, 1992
- A cDNA that suppresses MPP+ toxicity encodes a vesicular amine transporterCell, 1992
- Aspects on Diagnosis and Treatment of the Foregut Carcinoid SyndromeScandinavian Journal of Gastroenterology, 1992
- Increased dopamine production in patients with carcinoid tumorsMetabolism, 1985